EUCTR2012-004180-43-DK进行中（未招募）1 期
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS - Cardiovascular OutcoMes for People using Anticoagulation StrategieS) - COMPASS
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 29,940
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-- Coronary or peripheral artery disease
- •Patients with coronary artery disease must also meet at least one of the following:
- •-- Age =65, or
- •-- Age <65 and documented atherosclerosis or revascularization involving at least 2 vascular beds, or at least 2 additional risk factors
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4491
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25449
排除标准
- •-Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy or oral anticoagulant therapy
- •-Stroke within 1 month or any history of hemorrhagic or lacunar stroke
- •-Severe heart failure with known ejection fraction <30% or New York Heart Association (NYHA) class III or IV symptoms
- •-Estimated glomerular filtration rate (eGFR) <15 mL/min
研究者
相似试验
进行中（未招募）
1 期
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery diseasePrevention of major cardiovascular events in patients with coronary or peripheral artery diseaseMedDRA version: 20.0Level: PTClassification code 10064939Term: Cardiovascular event prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-004180-43-SKBayer AG29,940
进行中（未招募）
1 期
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery diseasePrevention of major cardiovascular events in patients with coronary or peripheral artery diseaseMedDRA version: 20.0Level: PTClassification code 10064939Term: Cardiovascular event prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-004180-43-FIBayer AG29,940
进行中（未招募）
1 期
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery diseaseEUCTR2012-004180-43-BEBayer AG29,940
进行中（未招募）
不适用
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery diseaseEUCTR2012-004180-43-ITBayer HealthCare AG21,500
进行中（未招募）
1 期
Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery diseasePrevention of major cardiovascular events in patients with coronary or peripheral artery diseaseMedDRA version: 18.0Level: PTClassification code 10064939Term: Cardiovascular event prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2012-004180-43-HUBayer HealthCare AG29,940